Main Profile
Manufacturer and marketer globally and a marketer in Turkey
Description in a few words:
Daiichi Sankyo, a Japanese multinational pharmaceutical company, offers a wide range of innovative medicines, mainly for cardiovascular and oncologic disorders. Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging its world-class science and technology.
Current Leadership:
Sunao Manabe, President & CEO,
Daiichi Sankyo Company, Limited
Jan Van Ruymbeke, Managing Director, CEO,
Daiichi Sankyo Europe GmbH)
Fatih Yedikardeş, General Manager,
Daiichi Sankyo Türkiye
Founding Year: 2007
“As a research-based pharmaceutical company, we focus on providing solutions to address patients' needs in cardiology and oncology areas. Our competitive advantage is in oncology, and as part of our 2025 vision, the U.S. Food and Drug Administration approved our second product in 2019.”
Manufacturing
Number of machinery in Production and capacities: solid, liquid, sterile
90% of products are on sale in Turkish market and being manufactured at production facilities in Abdi İbrahim İlaç in Turkey.
- Solid production + packaging
- Liquid and semi-solid production + packaging
- Dispensing and others
- Total production + packaging
- QC Laboratories (including Micro)
Main product categories or therapies of focus
Cardiovascular
Number of APIs produced
Product Forms: Tablets, film coated tablets, solutions (Prepared considering products are on sale in Turkey)
Primary packaging production
Blisters and bottles (Prepared considering products are on sale in Turkey)
In More Depth
Number of employees
Globally (Including Turkey): 15,000
In Turkey: 80
GMP certificates
. Revenue 2018 (globally): approx. ¥930 billion (€7.2 billion)*
*As of 31 March 2019
. Exchange rate: 128.40 Yen/EUR (average rate for year)
Source: Consolidated Financial Results for Year Ended March 31, 2019 (Fiscal 2018)
USP/ or a differentiating fact:
Daiichi Sankyo is the first company to discover vitamin B1 and establish a foundation for the theory of vitamins and also launched an adrenalin-producing antibiotic in Japan, with Prevastin in 1989, which was a globally groundbreaking antihyperlipidemic agent.
Prominent partnerships/ clients
Partner with Abdi İbrahim İlaç since 2019
Contact:
Website: